Has Aurobindo Pharma left its wild swings behind?

The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.

29 November, 20236 min
0
Banner image

Subscribe to read this story

We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.

$99 for one year

SUBSCRIBE
Already have an account? Sign In

Not ready to subscribe? Sign up for a free account

We value our free readers. Read 100+ stories every year.

You may also like

Business
Story image

Natco just can’t kick its high-risk, high-gain game plan

CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?

Business
Story image

Wockhardt urgently needs Rs 400 crore and its two wonder drugs

A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?

Business
Story image

Laurus Labs is Indian pharma’s dark horse

With a promoter who is unafraid to make bold bets and pivot to businesses holding more promise, investors can only look forward to better times.